Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000083663 | SCV000340737 | pathogenic | not provided | 2016-04-15 | criteria provided, single submitter | clinical testing | |
Genetic Services Laboratory, |
RCV000288398 | SCV000597254 | likely pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2017-05-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000288398 | SCV000631431 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2025-01-20 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 227 of the SRD5A2 protein (p.Arg227Gln). This variant is present in population databases (rs9332964, gnomAD 0.6%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individuals with steroid 5-alpha-reductase deficiency (PMID: 12843198, 14594182, 19342739, 20736251, 22453073, 25605705, 25899528). It is commonly reported in individuals of East Asian ancestry (PMID: 12843198, 14594182, 19342739, 20736251, 22453073, 25605705, 25899528). ClinVar contains an entry for this variant (Variation ID: 3351). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SRD5A2 protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects SRD5A2 function (PMID: 10898110). For these reasons, this variant has been classified as Pathogenic. |
SIB Swiss Institute of Bioinformatics | RCV000288398 | SCV000803498 | likely pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2018-05-31 | criteria provided, single submitter | curation | This variant is interpreted as a Likely Pathogenic, for Pseudovaginal perineoscrotal hypospadias, in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PS3 => Well-established functional studies show a deleterious effect (PMID:10898110). PM2-Supporting => PM2 downgraded in strength to Supporting. PS4-Supporting => PS4 downgraded in strength to Supporting. Recurrently seen in non-related affected individuals (PMID:25899528). PM3-Supporting => PM3 downgraded in strength to Supporting (PMID:15064320). |
Department of Medical Genetics, |
RCV000288398 | SCV001422496 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2019-11-15 | criteria provided, single submitter | clinical testing | This variant, NM_000348.4:c.680G>A, was found in compound heterozygosity with the pathogenic variant NM_000348.4:c.485A>C. |
Victorian Clinical Genetics Services, |
RCV000288398 | SCV002557885 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2023-07-17 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with 46,XY disorder of sex development due to 5-alpha-reductase 2 deficiency (MONDO:0009923). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to glutamine. (I) 0252 - This variant is homozygous. (I) 0304 - Variant is present in gnomAD (v3) <0.01 for a recessive condition (32 heterozygotes, 1 homozygote). (SP) 0504 - Same amino acid change has been observed in placental mammals. (SB) 0600 - Variant is located in the annotated 3-oxo-5-alpha-steroid 4-dehydrogenase domain (NCBI). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. The variant has been previously reported in multiple East Asian patients with 5α-reductase 2 deficiency (ClinVar, PMID: 32713132). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. Functional studies show that this variant causes reduced enzyme activity (PMID: 10898110). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |
Fulgent Genetics, |
RCV000288398 | SCV005663644 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2024-04-24 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000003515 | SCV000023673 | pathogenic | Micropenis | 2003-07-01 | no assertion criteria provided | literature only | |
University of Sydney Medical Foundation | RCV000083663 | SCV000115749 | not provided | not provided | no assertion provided | not provided | ||
Clinical Molecular Genetics Laboratory, |
RCV000288398 | SCV000692398 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2016-04-12 | no assertion criteria provided | clinical testing | |
Reproductive Health Research and Development, |
RCV000288398 | SCV001142316 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2020-01-06 | no assertion criteria provided | curation | NM_000348.3:c.680G>A in the SRD5A2 gene has an allele frequency of 0.006 in East Asian subpopulation in the gnomAD database. Cheng J et al. reported that the c.680G>A (p.Arg227Gln) mutation was identified in 16 homozygous patients, 17 compound heterozygous patients, eight heterozygous patients with 5-alpha-reductase type 2 deficiency (PMID: 25899528 ). Experimental studies have shown that this missense change reduces enzyme activity (PMID: 10898110). In addition, Cancio et al. reported a male pseudohermaphrodite patient harboring R227Q with a frameshift mutation from codon 219. These two variants were located in a different allele (PMID: 15064320). Taken together, we interprete this variant as Pathogenic/Likely pathogenic variant. ACMG/AMP Criteria applied: PS3, PM3_Strong, PP4. |
Beijing Key Laboratory for Genetic Research of Skeletal Deformity, |
RCV000288398 | SCV001482343 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | 2019-05-31 | no assertion criteria provided | research | |
Gene Friend Way, |
RCV003313913 | SCV004013902 | likely pathogenic | Autism spectrum disorder | 2023-07-28 | no assertion criteria provided | clinical testing | A nonsynonymous change known as R227Q in the SRD5A2 gene. The SRD5A2 gene encodes steroid 5-alpha-reductase, an enzyme which catalyzes the conversion of testosterone in the body. Some research shows that there is a role for the adrenal glands in ASD (PMID: 34493761). Variants of SRD5A2 related to autism/ autistic-like traits have been reported (PMID: 35042285, 23867117). |
Seattle Children's Hospital Molecular Genetics Laboratory, |
RCV000288398 | SCV004174101 | pathogenic | 3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003944795 | SCV004762852 | likely pathogenic | SRD5A2-related disorder | 2024-05-20 | no assertion criteria provided | clinical testing | The SRD5A2 c.680G>A variant is predicted to result in the amino acid substitution p.Arg227Gln. This variant has been reported in the homozygous and compound heterozygous states in multiple individuals with steroid 5-alpha-reductase deficiency (see for example, Table 2, Hiort et al. 1996. PubMed ID: 8784107; Table 1, Kon et al. 2015. PubMed ID: 25605705; Table 2, Zhang et al. 2019. PubMed ID: 31219235). This variant is reported in 0.67% of alleles in individuals of East Asian descent in gnomAD. An in vitro experimental study has shown this variant markedly reduces enzyme activity (Table 2, Makridakis et al. 2000. PubMed ID: 10898110). This variant is interpreted as likely pathogenic. |